Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioLife Solutions, Inc. - Common Stock (NQ:BLFS)

22.84 +0.09 (+0.40%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 503,412
Open 23.02
Bid (Size) 22.53 (2)
Ask (Size) 25.00 (50)
Prev. Close 22.75
Today's Range 22.48 - 23.34
52wk Range 18.70 - 29.55
Shares Outstanding 47,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BLFS Stock Earnings: BioLife Solns Beats EPS, Beats Revenue for Q2 2024
BLFS stock results show that BioLife Solns beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
BLFS Stock Earnings: BioLife Solns Beats EPS, Beats Revenue for Q1 2024
BLFS stock results show that BioLife Solns beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-12.8%
-12.8%
1 Month
+6.2%
+6.2%
3 Month
+4.1%
+4.1%
6 Month
-16.2%
-16.2%
1 Year
+14.2%
+14.2%

More News

Read More
Meta Platforms, Pure Storage And 2 Other Stocks Insiders Are Selling
Via Benzinga
BioLife Solns: Q3 Earnings Insights
Via Benzinga
Over $1M Bet On Carnival? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Top 5 Health Care Stocks That Could Blast Off This Month
Via Benzinga
BioLife Solns: Q1 Earnings Insights
Via Benzinga
BioLife Solutions's Earnings Outlook
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
Exploring BioLife Solns's Earnings Expectations
Via Benzinga
Earnings Scheduled For March 3, 2025
Via Benzinga
Analyst Expectations For BioLife Solns's Future
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Key Takeaways From BioLife Solns Analyst Ratings
Via Benzinga
Recap: BioLife Solns Q4 Earnings
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
Earnings Preview For BioLife Solns
Via Benzinga
Why Shares of BioLife Solutions Plummeted This Week
Via The Motley Fool
Why Cutera Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Wednesday's Session
Via Benzinga
Why Shares of BioLife Solutions Are Slumping on Wednesday
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023
Via Benzinga

Frequently Asked Questions

Is BioLife Solutions, Inc. - Common Stock publicly traded?
Yes, BioLife Solutions, Inc. - Common Stock is publicly traded.
What exchange does BioLife Solutions, Inc. - Common Stock trade on?
BioLife Solutions, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioLife Solutions, Inc. - Common Stock?
The ticker symbol for BioLife Solutions, Inc. - Common Stock is BLFS on the Nasdaq Stock Market
What is the current price of BioLife Solutions, Inc. - Common Stock?
The current price of BioLife Solutions, Inc. - Common Stock is 22.84
When was BioLife Solutions, Inc. - Common Stock last traded?
The last trade of BioLife Solutions, Inc. - Common Stock was at 07/03/25 01:00 PM ET
What is the market capitalization of BioLife Solutions, Inc. - Common Stock?
The market capitalization of BioLife Solutions, Inc. - Common Stock is 1.08B
How many shares of BioLife Solutions, Inc. - Common Stock are outstanding?
BioLife Solutions, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.